BTAI
BioXcel Therapeutics, Inc.$1.16+0.05 (+4.50%)Prev Close$1.11·MCap$29.5M·P/E—·Vol429.6K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
4
$43.1K
◆
Net Activity
Net Seller
$43.1K
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at BioXcel Therapeutics, Inc. (BTAI) has been exclusively selling, with 0 insider purchases totaling $0.00 and 4 insider sales totaling $43.1K. The most recent insider transaction was by Mehta Vimal (director, officer: CEO and President), who sold $21.1K worth of shares on May 22, 2026. BioXcel Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $29.5M.
BTAI Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Mehta Vimal | director, officer: CEO and President | Sell | 19,419 | $1.09 | $21.1K | 69,598 |
| May 22, 2026 | Steinhart Richard I | officer: Chief Financial Officer | Sell | 6,845 | $1.08 | $7.4K | 26,300 |
| May 22, 2026 | Rodriguez Javier | officer: See Remarks | Sell | 6,560 | $1.08 | $7.1K | 26,803 |
| May 22, 2026 | Yocca Frank | officer: Chief Scientific Officer | Sell | 6,845 | $1.08 | $7.4K | 26,175 |
| Dec 14, 2024 | Mehta Vimal | CEO and President | Sell | 3,117 | $0.36 | $1.1K | 0 |
| Dec 14, 2024 | O'Neill Vincent | See Remarks | Sell | 165 | $0.35 | $58.13 | 0 |
| Dec 14, 2024 | Rodriguez Javier | See Remarks | Sell | 430 | $0.36 | $153.02 | 0 |
| Dec 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 577 | $0.36 | $206.98 | 0 |
| Dec 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 225 | $0.35 | $79.02 | 0 |
| Sep 17, 2024 | O'Neill Vincent | See Remarks | Sell | 5,556 | $0.55 | $3.1K | 0 |
| Sep 17, 2024 | Rodriguez Javier | See Remarks | Sell | 6,863 | $0.55 | $3.8K | 0 |
| Sep 17, 2024 | Wiley Matthew T. | Chief Commercial Officer | Sell | 6,272 | $0.55 | $3.4K | 0 |
| Sep 17, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 7,175 | $0.55 | $3.9K | 0 |
| Sep 15, 2024 | Wiley Matthew T. | Chief Commercial Officer | Sell | 215 | $0.69 | $148.52 | 0 |
| Sep 14, 2024 | Mehta Vimal | CEO and President | Sell | 1,982 | $0.69 | $1.4K | 0 |
| Sep 14, 2024 | O'Neill Vincent | See Remarks | Sell | 138 | $0.69 | $95.33 | 0 |
| Sep 14, 2024 | Rodriguez Javier | See Remarks | Sell | 345 | $0.69 | $238.05 | 0 |
| Sep 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 356 | $0.69 | $245.60 | 0 |
| Sep 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 355 | $0.69 | $244.70 | 0 |
| Jun 15, 2024 | Wiley Matthew T. | Chief Commercial Officer | Sell | 244 | $1.26 | $308.10 | 0 |
| Jun 14, 2024 | Mehta Vimal | CEO and President | Sell | 2,134 | $1.28 | $2.7K | 0 |
| Jun 14, 2024 | O'Neill Vincent | See Remarks | Sell | 155 | $1.28 | $199.17 | 0 |
| Jun 14, 2024 | Rodriguez Javier | See Remarks | Sell | 361 | $1.26 | $456.02 | 0 |
| Jun 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 372 | $1.26 | $469.54 | 0 |
| Jun 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 372 | $1.28 | $476.16 | 0 |
| Jun 4, 2024 | Mehta Vimal | CEO and President | Sell | 252,028 | $1.61 | $405.1K1.0% OS | 0 |
| Mar 15, 2024 | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | Sell | 1,008 | $2.64 | $2.7K | 0 |
| Mar 14, 2024 | Mehta Vimal | CEO and President | Sell | 5,268 | $2.62 | $13.8K | 0 |
| Mar 14, 2024 | O'Neill Vincent | See Remarks | Sell | 165 | $2.62 | $432.48 | 0 |
| Mar 14, 2024 | Rodriguez Javier | See Remarks | Sell | 1,012 | $2.64 | $2.7K | 0 |
| Mar 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 1,069 | $2.63 | $2.8K | 0 |
| Mar 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 1,067 | $2.63 | $2.8K | 0 |
| Jun 14, 2023 | Mehta Vimal | CEO and President | Sell | 60,000 | $20.86 | $1.25M | 0 |
| May 22, 2023 | Mehta Vimal | CEO and President | Sell | 6,500 | $25.79 | $167.6K | 0 |
| May 14, 2023 | Rodriguez Javier | See Remarks | Sell | 1,785 | $27.32 | $48.8K | 0 |
| May 14, 2023 | Steinhart Richard I | Chief Financial Officer | Sell | 5,000 | $27.17 | $135.9K | 0 |
| Apr 6, 2023 | Nandabalan Krishnan | Director | Sell | 60,000 | $17.32 | $1.04M | 0 |
| Mar 20, 2023 | Mehta Vimal | CEO and President | Sell | 64,500 | $18.97 | $1.22M | 0 |
| Mar 14, 2023 | O'Neill Vincent | Chief Medical Officer | Sell | 845 | $19.70 | $16.6K | 0 |
| Mar 14, 2023 | Rodriguez Javier | See Remarks | Sell | 950 | $19.63 | $18.6K | 0 |
| Mar 14, 2023 | Steinhart Richard I | Chief Financial Officer | Sell | 2,084 | $19.50 | $40.6K | 0 |
| Mar 14, 2023 | Yocca Frank | Chief Scientific Officer | Sell | 985 | $19.69 | $19.4K | 0 |
| Jan 20, 2023 | O'Neill Vincent | Chief Medical Officer | Sell | 29,713 | $30.00 | $891.4K | 0 |
| Jan 20, 2023 | Yocca Frank | Chief Scientific Officer | Sell | 50,000 | $30.00 | $1.50M | 0 |
| Jan 4, 2023 | Nandabalan Krishnan | Director | Sell | 60,000 | $22.01 | $1.32M | 0 |
| Dec 15, 2022 | Mehta Vimal | CEO and President | Sell | 60,000 | $19.69 | $1.18M | 0 |
| Nov 10, 2022 | Nandabalan Krishnan | Director | Sell | 60,000 | $15.00 | $900.0K | 0 |
| Jun 25, 2021 | Mehta Vimal | CEO, President and Secretary | Sell | 473,250 | $30.83 | $14.59M1.9% OS | 0 |
| Mar 15, 2021 | Yocca Frank | Chief Scientific Officer | Sell | 15,000 | $48.50 | $727.6K | 0 |
BTAI Insider Buying Activity
The following table shows recent insider purchases of BioXcel Therapeutics, Inc. (BTAI) stock reported via SEC Form 4 filings.
No insider buying activity found for BTAI in the last 12 months.
BTAI Insider Selling Activity
The following table shows recent insider sales of BioXcel Therapeutics, Inc. (BTAI) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Mehta Vimal | director, officer: CEO and President | Sell | 19,419 | $1.09 | $21.1K | 69,598 |
| May 22, 2026 | Steinhart Richard I | officer: Chief Financial Officer | Sell | 6,845 | $1.08 | $7.4K | 26,300 |
| May 22, 2026 | Rodriguez Javier | officer: See Remarks | Sell | 6,560 | $1.08 | $7.1K | 26,803 |
| May 22, 2026 | Yocca Frank | officer: Chief Scientific Officer | Sell | 6,845 | $1.08 | $7.4K | 26,175 |
| Dec 14, 2024 | Mehta Vimal | CEO and President | Sell | 3,117 | $0.36 | $1.1K | 0 |
| Dec 14, 2024 | O'Neill Vincent | See Remarks | Sell | 165 | $0.35 | $58.13 | 0 |
| Dec 14, 2024 | Rodriguez Javier | See Remarks | Sell | 430 | $0.36 | $153.02 | 0 |
| Dec 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 577 | $0.36 | $206.98 | 0 |
| Dec 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 225 | $0.35 | $79.02 | 0 |
| Sep 17, 2024 | O'Neill Vincent | See Remarks | Sell | 5,556 | $0.55 | $3.1K | 0 |
| Sep 17, 2024 | Rodriguez Javier | See Remarks | Sell | 6,863 | $0.55 | $3.8K | 0 |
| Sep 17, 2024 | Wiley Matthew T. | Chief Commercial Officer | Sell | 6,272 | $0.55 | $3.4K | 0 |
| Sep 17, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 7,175 | $0.55 | $3.9K | 0 |
| Sep 15, 2024 | Wiley Matthew T. | Chief Commercial Officer | Sell | 215 | $0.69 | $148.52 | 0 |
| Sep 14, 2024 | Mehta Vimal | CEO and President | Sell | 1,982 | $0.69 | $1.4K | 0 |
| Sep 14, 2024 | O'Neill Vincent | See Remarks | Sell | 138 | $0.69 | $95.33 | 0 |
| Sep 14, 2024 | Rodriguez Javier | See Remarks | Sell | 345 | $0.69 | $238.05 | 0 |
| Sep 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 356 | $0.69 | $245.60 | 0 |
| Sep 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 355 | $0.69 | $244.70 | 0 |
| Jun 15, 2024 | Wiley Matthew T. | Chief Commercial Officer | Sell | 244 | $1.26 | $308.10 | 0 |
| Jun 14, 2024 | Mehta Vimal | CEO and President | Sell | 2,134 | $1.28 | $2.7K | 0 |
| Jun 14, 2024 | O'Neill Vincent | See Remarks | Sell | 155 | $1.28 | $199.17 | 0 |
| Jun 14, 2024 | Rodriguez Javier | See Remarks | Sell | 361 | $1.26 | $456.02 | 0 |
| Jun 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 372 | $1.26 | $469.54 | 0 |
| Jun 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 372 | $1.28 | $476.16 | 0 |
| Jun 4, 2024 | Mehta Vimal | CEO and President | Sell | 252,028 | $1.61 | $405.1K1.0% OS | 0 |
| Mar 15, 2024 | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | Sell | 1,008 | $2.64 | $2.7K | 0 |
| Mar 14, 2024 | Mehta Vimal | CEO and President | Sell | 5,268 | $2.62 | $13.8K | 0 |
| Mar 14, 2024 | O'Neill Vincent | See Remarks | Sell | 165 | $2.62 | $432.48 | 0 |
| Mar 14, 2024 | Rodriguez Javier | See Remarks | Sell | 1,012 | $2.64 | $2.7K | 0 |
| Mar 14, 2024 | Steinhart Richard I | Chief Financial Officer | Sell | 1,069 | $2.63 | $2.8K | 0 |
| Mar 14, 2024 | Yocca Frank | Chief Scientific Officer | Sell | 1,067 | $2.63 | $2.8K | 0 |
| Jun 14, 2023 | Mehta Vimal | CEO and President | Sell | 60,000 | $20.86 | $1.25M | 0 |
| May 22, 2023 | Mehta Vimal | CEO and President | Sell | 6,500 | $25.79 | $167.6K | 0 |
| May 14, 2023 | Rodriguez Javier | See Remarks | Sell | 1,785 | $27.32 | $48.8K | 0 |
| May 14, 2023 | Steinhart Richard I | Chief Financial Officer | Sell | 5,000 | $27.17 | $135.9K | 0 |
| Apr 6, 2023 | Nandabalan Krishnan | Director | Sell | 60,000 | $17.32 | $1.04M | 0 |
| Mar 20, 2023 | Mehta Vimal | CEO and President | Sell | 64,500 | $18.97 | $1.22M | 0 |
| Mar 14, 2023 | O'Neill Vincent | Chief Medical Officer | Sell | 845 | $19.70 | $16.6K | 0 |
| Mar 14, 2023 | Rodriguez Javier | See Remarks | Sell | 950 | $19.63 | $18.6K | 0 |
| Mar 14, 2023 | Steinhart Richard I | Chief Financial Officer | Sell | 2,084 | $19.50 | $40.6K | 0 |
| Mar 14, 2023 | Yocca Frank | Chief Scientific Officer | Sell | 985 | $19.69 | $19.4K | 0 |
| Jan 20, 2023 | O'Neill Vincent | Chief Medical Officer | Sell | 29,713 | $30.00 | $891.4K | 0 |
| Jan 20, 2023 | Yocca Frank | Chief Scientific Officer | Sell | 50,000 | $30.00 | $1.50M | 0 |
| Jan 4, 2023 | Nandabalan Krishnan | Director | Sell | 60,000 | $22.01 | $1.32M | 0 |
| Dec 15, 2022 | Mehta Vimal | CEO and President | Sell | 60,000 | $19.69 | $1.18M | 0 |
| Nov 10, 2022 | Nandabalan Krishnan | Director | Sell | 60,000 | $15.00 | $900.0K | 0 |
| Jun 25, 2021 | Mehta Vimal | CEO, President and Secretary | Sell | 473,250 | $30.83 | $14.59M1.9% OS | 0 |
| Mar 15, 2021 | Yocca Frank | Chief Scientific Officer | Sell | 15,000 | $48.50 | $727.6K | 0 |
BTAI Insiders
Similar Stocks to BTAI
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B